Together with a team of Sobi colleagues, I will be cycling about 460 km from Bonn to Hamburg over four days from Thursday August 29 to Sunday 1 September in order to raise money for the European Haemophilia Consortium (EHC). The funds are used to support projects for increased physical activity and an active life style for haemophilia patients.
I was on the ride in 2017 from Paris to Brussels and now I am going for the second time - well aware of the physical challenge of cycling a long distance for several days in a row. Still, I am nothing but happy to again team up with my colleagues in a joint effort to raise funding and not the least awareness about the challenges facing people with haemophilia. It will be a lot of sweat and a lot of fun - there is nothing more motivating than working in a team for an important cause. Your support for my fundraising to the EHC would be so appreciated and help fuel my pedaling all the 460 km!
This is the fourth stage of the Sobi Charity bike ride for Haemophilia that started in 2016 from London to Paris, continued in 2017 from Paris to Brussels, Brussels-Mainz (Bonn) in 2018 and now in 2019 we cover the distance from Bonn to Hamburg. Finally one year this project may end up having cycled all the way from London to Stockholm and hopefully made a significant contribution to the haemophilia community.
About the EHC
The European Haemophilia Consortium (EHC) is an international non-profit organisation that represents 46 national patients’ organisations of people with rare bleeding disorders from 27 Member States of the European Union (EU) and most Member States of the Council of Europe. The EHC represents approximately 90,000 people diagnosed with a rare bleeding condition such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe. However, it is estimated that many more live with an undiagnosed rare bleeding disorder.
Haemophilia is a type of bleeding disorder in which the blood does not clot properly. When a person with haemophilia bleeds it takes longer than normal for the bleeding to stop. This is because people with haemophilia don’t produce enough of an important protein that helps the blood to clot, called a ‘clotting factor’. Haemophilia is a rare disease that is usually inherited and is more common in males than females.
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.